• NeuroFlow

  Participated · Series A · Dec 2019

  NeuroFlow provides a behavioral health SaaS platform that combines AI-driven analytics, care collaboration enablement, and enterprise consumer-grade activation. The platform identifies, manages, and monitors complex behavioral health and substance use populations and makes population intelligence actionable for providers and care managers by integrating into the delivery workflow. It supplies evidence-based decision support to ensure appropriate care and engages consumers through the integrated workflow to improve treatment adherence. NeuroFlow also offers a safety net of capabilities between clinical and non-clinical interactions. Led by CEO Chris Molaro and based in Philadelphia, the company received an investment from Concord Health Plans; the amount and instrument were not disclosed. The company intends to use the funds to expand operations and its business reach within complex payor and government agency segments. NeuroFlow provides a behavioral health integration platform that assesses and triages people with behavioral health conditions to connect them to the right level of care. Its platform combines consumer engagement with care-management software to support behavioral health at scale and has been shown to drive clinical and financial outcomes for hundreds of leading health systems, payors, and military organizations. The company reports its platform now covers 15 million individuals, up from 2 million within the past year, with adoption across all 50 states. NeuroFlow plans to use new funding to expand its technology platform and referral network and to deepen relationships with payors and providers. Led by CEO Chris Molaro, the company doubled its full-time headcount over the past year and recently moved into a 16,000-square-foot office in downtown Philadelphia to support growth and partner collaboration. NeuroFlow offers a HIPAA-compliant, cloud-based suite of tools that support collaborative and measurement-based behavioral health across care settings. Its platform simplifies remote patient monitoring, improves risk stratification, and facilitates collaborative care workflows. The company reports approximately 25,000 patients on its platform and deployments at more than 200 healthcare facilities. Led by CEO and co-founder Chris Molaro, NeuroFlow integrates with care settings to support clinicians and care teams. The company plans to use the Series A proceeds to expand its team and further invest in product integrations and data science to continue building its comprehensive behavioral health and collaborative care platform. NeuroFlow is based in Philadelphia, PA. NeuroFlow operates a mental-health platform that tracks biometric data to support mental health professionals. The platform is already up and running. The company plans to use the new capital to hire a data scientist and an engineer and to ramp up sales and marketing. NeuroFlow is based in Center City. Cofounder and CEO Christopher Molaro said the definitive SEC filing should be submitted in the next few weeks. The article reports an initial raise of $906,000 that was topped off by the recent financing.

No current team members are available.